A Pilot Study of Aerosolized Amiloride for the Treatment of Lung Disease in Cystic Fibrosis
- 26 April 1990
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 322 (17), 1189-1194
- https://doi.org/10.1056/nejm199004263221704
Abstract
Excessive active absorption of sodium is a unique abnormality of the airway epithelium in patients with cystic fibrosis. This defect is associated with thickened mucus and poor clearance of airway secretions and may contribute to the pulmonary disease in these patients. To study whether the inhibition of excessive absorption of sodium might affect the course of lung disease in cystic fibrosis, we performed a double-blind, crossover trial comparing aerosolized amiloride (5 mmol per liter; 3.5 ml four times daily), a sodium-channel blocker, with vehicle alone. Fourteen of the 18 adult patients initially enrolled in the study completed the one-year trial (25 weeks for each treatment). The mean (±SEM) loss of forced vital capacity (FVC) was reduced from 3.39±1.13 ml per day during treatment with vehicle alone to 1.44±0.67 ml per day during treatment with amiloride (P<0.04). A measured index of sputum viscosity and elasticity was abnormal during treatment with vehicle alone and improved during treatment with amiloride. Calculated indexes of mucociliary and cough clearance also improved during amiloride treatment. No systemic, respiratory, or subjective toxic effects of amiloride were noted. We conclude from this preliminary study that aerosolized amiloride can be safely administered to adults with cystic fibrosis. The slowing of the loss of FVC and the improvement in sputum viscosity and elasticity suggest a beneficial clinical effect. Aerosolized amiloride deserves further evaluation in the treatment of lung disease in patients with cystic fibrosis. (N Engl J Med 1990; 322: 1189–94.)Keywords
This publication has 17 references indexed in Scilit:
- Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosisThe Journal of Pediatrics, 1988
- In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosisAntimicrobial Agents and Chemotherapy, 1988
- Cyclic AMP-dependent protein kinase opens chloride channels in normal but not cystic fibrosis airway epitheliumNature, 1988
- Phosphorylation fails to activate chloride channels from cystic fibrosis airway cellsNature, 1987
- Standardization of Spirometry—1987 UpdateAmerican Review of Respiratory Disease, 1987
- Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation.JCI Insight, 1986
- Altered Regulation of Airway Epithelial Cell Chloride Channels in Cystic FibrosisScience, 1986
- Relative ion permeability of normal and cystic fibrosis nasal epithelium.JCI Insight, 1983
- MICROBIOLOGY OF LUNG INFECTIONS IN CYSTIC FIBROSIS PATIENTSActa Paediatrica, 1982
- Increased Bioelectric Potential Difference across Respiratory Epithelia in Cystic FibrosisThe New England Journal of Medicine, 1981